Breaking News: Trend Chart on Innovative Bioindustries (July 29th)

Breaking News: Trend Chart on Innovative Bioindustries (July 29th)

Trend Chart on Innovative BioIndustries is a FREE NEWSLETTER published by BioPharmAnalyses and OctopusyX BioConsulting. Do not hesitate to share it with colleagues and anybody who may be interested in these topics. Contents of the last issue. -GSK and CureVac announce strategic mRNA technology collaboration. -Gene therapy development in hearing research in China. -Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. -Moderna announces interim results from Phase 1 Study of its mRNA vaccine against COVID-19. -Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. -Biogen plans to initiate phase 4 study evaluating benefit of Spinraza® in patients ...
Read More
Evotec and Secarna Pharmaceuticals form strategic partnership in the field of antisense therapy

Evotec and Secarna Pharmaceuticals form strategic partnership in the field of antisense therapy

Evotec SE and a leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG announced onAugust 05th a strategic partnership in the field of antisense oligonucleotide (“ASO”)-based therapeutics. Antisense therapy is an innovative, clinically and commercially validated, highly-targeted pharmacological approach which interferes with gene expression in the cells of interest to specifically inhibit the production of proteins which promote development and progression of diseases. Secarna is the next generation antisense drug discovery company, combining its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate molecules with significantly improved potency and a comprehensive safety profile against targets ...
Read More
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Sangamo Therapeutics, Inc., a genomic medicine company, today announced on July 30th that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders. The collaboration will leverage Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), to aim to upregulate the expression of key genes involved in neurodevelopmental disorders. For further information, see Businesswire(https://www.businesswire.com/news/home/20200730005166/en/) ...
Read More
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, announced on July 29th that it has raised $31 million (€27 million) in a Series A financing round. Vico will use this funding to further advance its late preclinical stage Antisense OligoNucleotides (AON) lead platform for the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinical trials in late 2021. Its early discovery RNA editing platform is directed towards RETT syndrome. The financing was led by Life Science Partners (LSP), co-led by Kurma Partners, and supported ...
Read More
Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced on July 28th a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published in The New England Journal of Medicine . The study showed a two-dose vaccination schedule of mRNA-1273 led to a robust immune response and protection against SARS-CoV-2 infection in the upper and lower airways in non-human primates, without evidence of vaccine-associated enhanced respiratory disease (VAERD). In the study, immunogenicity and protective efficacy were assessed after a two-dose vaccination schedule of ...
Read More
Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

Moderna, Inc. announced on July 26th a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Company’s mRNA vaccine candidate (mRNA-1273) against COVID-19. An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated number of participants in the Phase 3 clinical trial. Following discussions with the U.S. Food and Drug Administration (FDA) and consultations with ...
Read More
Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies

Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies

Forge Biologics, a viral vector gene therapy manufacturing and development company with the dual platform of CDMO capabilities and the development of proprietary gene therapy products, announced on July 21st the closing of a $40 million Series A financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”) with participation from Drive Capital. Forge will use the proceeds of this financing to expand AAV manufacturing CDMO capabilities in 2020, with cGMP production capacity available by mid-2021, and for the development of a novel gene therapy pipeline. Forge Biologics is a viral vector CDMO and therapeutics developer, located in a 175,000 ...
Read More

Breaking News: Trend Chart on Innovative Bioindustries (July 29th)

Breaking News: Trend Chart on Innovative Bioindustries (July 29th)

Trend Chart on Innovative BioIndustries is a FREE NEWSLETTER published by BioPharmAnalyses and OctopusyX BioConsulting. Do not hesitate to share it with colleagues and anybody who may be interested in these topics. Contents of the last issue. -GSK and CureVac announce strategic mRNA technology collaboration. -Gene therapy development in hearing research in China. -Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. -Moderna announces interim results from Phase 1 Study of its mRNA vaccine against COVID-19. -Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. -Biogen plans to initiate phase 4 study evaluating benefit of Spinraza® in patients ...
Read More
Evotec and Secarna Pharmaceuticals form strategic partnership in the field of antisense therapy

Evotec and Secarna Pharmaceuticals form strategic partnership in the field of antisense therapy

Evotec SE and a leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG announced onAugust 05th a strategic partnership in the field of antisense oligonucleotide (“ASO”)-based therapeutics. Antisense therapy is an innovative, clinically and commercially validated, highly-targeted pharmacological approach which interferes with gene expression in the cells of interest to specifically inhibit the production of proteins which promote development and progression of diseases. Secarna is the next generation antisense drug discovery company, combining its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate molecules with significantly improved potency and a comprehensive safety profile against targets ...
Read More
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Sangamo Therapeutics, Inc., a genomic medicine company, today announced on July 30th that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders. The collaboration will leverage Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), to aim to upregulate the expression of key genes involved in neurodevelopmental disorders. For further information, see Businesswire(https://www.businesswire.com/news/home/20200730005166/en/) ...
Read More
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, announced on July 29th that it has raised $31 million (€27 million) in a Series A financing round. Vico will use this funding to further advance its late preclinical stage Antisense OligoNucleotides (AON) lead platform for the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinical trials in late 2021. Its early discovery RNA editing platform is directed towards RETT syndrome. The financing was led by Life Science Partners (LSP), co-led by Kurma Partners, and supported ...
Read More
Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced on July 28th a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published in The New England Journal of Medicine . The study showed a two-dose vaccination schedule of mRNA-1273 led to a robust immune response and protection against SARS-CoV-2 infection in the upper and lower airways in non-human primates, without evidence of vaccine-associated enhanced respiratory disease (VAERD). In the study, immunogenicity and protective efficacy were assessed after a two-dose vaccination schedule of ...
Read More
Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

Moderna, Inc. announced on July 26th a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Company’s mRNA vaccine candidate (mRNA-1273) against COVID-19. An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated number of participants in the Phase 3 clinical trial. Following discussions with the U.S. Food and Drug Administration (FDA) and consultations with ...
Read More
Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies

Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies

Forge Biologics, a viral vector gene therapy manufacturing and development company with the dual platform of CDMO capabilities and the development of proprietary gene therapy products, announced on July 21st the closing of a $40 million Series A financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”) with participation from Drive Capital. Forge will use the proceeds of this financing to expand AAV manufacturing CDMO capabilities in 2020, with cGMP production capacity available by mid-2021, and for the development of a novel gene therapy pipeline. Forge Biologics is a viral vector CDMO and therapeutics developer, located in a 175,000 ...
Read More
Breaking News: Trend Chart on Innovative Bioindustries (July 29th)

Breaking News: Trend Chart on Innovative Bioindustries (July 29th)

Trend Chart on Innovative BioIndustries is a FREE NEWSLETTER published by BioPharmAnalyses and OctopusyX BioConsulting. Do not hesitate to share it with colleagues and anybody who may be interested in these topics. Contents of the last issue. -GSK and CureVac announce strategic mRNA technology collaboration. -Gene therapy development in hearing research in China. -Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. -Moderna announces interim results from Phase 1 Study of its mRNA vaccine against COVID-19. -Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. -Biogen plans to initiate phase 4 study evaluating benefit of Spinraza® in patients ...
Read More
Evotec and Secarna Pharmaceuticals form strategic partnership in the field of antisense therapy

Evotec and Secarna Pharmaceuticals form strategic partnership in the field of antisense therapy

Evotec SE and a leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG announced onAugust 05th a strategic partnership in the field of antisense oligonucleotide (“ASO”)-based therapeutics. Antisense therapy is an innovative, clinically and commercially validated, highly-targeted pharmacological approach which interferes with gene expression in the cells of interest to specifically inhibit the production of proteins which promote development and progression of diseases. Secarna is the next generation antisense drug discovery company, combining its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate molecules with significantly improved potency and a comprehensive safety profile against targets ...
Read More
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Sangamo Therapeutics, Inc., a genomic medicine company, today announced on July 30th that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders. The collaboration will leverage Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), to aim to upregulate the expression of key genes involved in neurodevelopmental disorders. For further information, see Businesswire(https://www.businesswire.com/news/home/20200730005166/en/) ...
Read More
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, announced on July 29th that it has raised $31 million (€27 million) in a Series A financing round. Vico will use this funding to further advance its late preclinical stage Antisense OligoNucleotides (AON) lead platform for the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinical trials in late 2021. Its early discovery RNA editing platform is directed towards RETT syndrome. The financing was led by Life Science Partners (LSP), co-led by Kurma Partners, and supported ...
Read More
Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced on July 28th a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published in The New England Journal of Medicine . The study showed a two-dose vaccination schedule of mRNA-1273 led to a robust immune response and protection against SARS-CoV-2 infection in the upper and lower airways in non-human primates, without evidence of vaccine-associated enhanced respiratory disease (VAERD). In the study, immunogenicity and protective efficacy were assessed after a two-dose vaccination schedule of ...
Read More
Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

Moderna, Inc. announced on July 26th a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Company’s mRNA vaccine candidate (mRNA-1273) against COVID-19. An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated number of participants in the Phase 3 clinical trial. Following discussions with the U.S. Food and Drug Administration (FDA) and consultations with ...
Read More
Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies

Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies

Forge Biologics, a viral vector gene therapy manufacturing and development company with the dual platform of CDMO capabilities and the development of proprietary gene therapy products, announced on July 21st the closing of a $40 million Series A financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”) with participation from Drive Capital. Forge will use the proceeds of this financing to expand AAV manufacturing CDMO capabilities in 2020, with cGMP production capacity available by mid-2021, and for the development of a novel gene therapy pipeline. Forge Biologics is a viral vector CDMO and therapeutics developer, located in a 175,000 ...
Read More